Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly & Company (NYSE: LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Eli Lilly and Company (NYSE: LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly is the safer bet, as it has a deep lineup and pipeline of products, generates significant revenue that has been ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

EMA committee recommends approval of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease: Indianapolis Monday, July 28, 2025, 13:00 Hrs [IST] Eli Lilly and Company an ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...